Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (11-20 of 252) with videos related to

Pageof 26
Sort By:
Leukemia & Lymphoma|January 2, 2025
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectivesDennis A Eichenauer, Peter Borchmann
British Journal of Haematology|March 9, 2022
Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefitsPaul J Bröckelmann, Peter Borchmann
The Lancet. Oncology|May 1, 2021
PET-guided omission of radiotherapy in Hodgkin lymphoma - Authors' replyPeter Borchmann, Annette Plütschow, Helen Görgen
The Lancet. Oncology|November 2, 2013
BEACOPP or no BEACOPP? - authors' replyPeter Borchmann, Nicole Skoetz, Sven Trelle, et al.
Journal of Behavioral Medicine|May 7, 2026
Methodological illustration using machine learning methods to predict cancer-related fatigue in cancer patientsNele Stadtbaeumer, Peter Borchmann, Axel Mayer
Nature Reviews. Clinical Oncology|October 6, 2011
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!Peter Borchmann, Andreas Engert, Volker Diehl
Expert Opinion on Emerging Drugs|July 16, 2010
Emerging drugs for Hodgkin's lymphomaBoris Böll, Peter Borchmann, Volker Diehl
Lancet (London, England)|April 5, 2025
PET evaluation in Hodgkin lymphoma: when to change treatment - Authors' replyJustin Ferdinandus, Gundolf Schneider, Peter Borchmann
The New England Journal of Medicine|October 21, 2011
ABVD versus BEACOPP for Hodgkin's lymphomaPeter Borchmann, Volker Diehl, Andreas Engert
Leukemia & Lymphoma|December 16, 2011
Adolescents with Hodgkin lymphoma: old children or young adults?Dennis A Eichenauer, Peter Borchmann, Andreas Engert
Pageof 26

Showing results (11-20 of 252) with videos related to

Sort By:
Pageof 26
Leukemia & Lymphoma|January 2, 2025
Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectivesDennis A Eichenauer, Peter Borchmann
British Journal of Haematology|March 9, 2022
Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefitsPaul J Bröckelmann, Peter Borchmann
The Lancet. Oncology|May 1, 2021
PET-guided omission of radiotherapy in Hodgkin lymphoma - Authors' replyPeter Borchmann, Annette Plütschow, Helen Görgen
The Lancet. Oncology|November 2, 2013
BEACOPP or no BEACOPP? - authors' replyPeter Borchmann, Nicole Skoetz, Sven Trelle, et al.
Journal of Behavioral Medicine|May 7, 2026
Methodological illustration using machine learning methods to predict cancer-related fatigue in cancer patientsNele Stadtbaeumer, Peter Borchmann, Axel Mayer
Nature Reviews. Clinical Oncology|October 6, 2011
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!Peter Borchmann, Andreas Engert, Volker Diehl
Expert Opinion on Emerging Drugs|July 16, 2010
Emerging drugs for Hodgkin's lymphomaBoris Böll, Peter Borchmann, Volker Diehl
Lancet (London, England)|April 5, 2025
PET evaluation in Hodgkin lymphoma: when to change treatment - Authors' replyJustin Ferdinandus, Gundolf Schneider, Peter Borchmann
The New England Journal of Medicine|October 21, 2011
ABVD versus BEACOPP for Hodgkin's lymphomaPeter Borchmann, Volker Diehl, Andreas Engert
Leukemia & Lymphoma|December 16, 2011
Adolescents with Hodgkin lymphoma: old children or young adults?Dennis A Eichenauer, Peter Borchmann, Andreas Engert
Pageof 26